CytomX Therapeutics, Inc. $CTMX Stake Raised by Elmind Capital LP

Elmind Capital LP lifted its stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 550.0% during the first quarter, HoldingsChannel.com reports. The firm owned 4,550,000 shares of the biotechnology company’s stock after purchasing an additional 3,850,000 shares during the period. CytomX Therapeutics accounts for about 6.1% of Elmind Capital LP’s portfolio, making the stock its 4th largest position. Elmind Capital LP’s holdings in CytomX Therapeutics were worth $21,385,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Wells Fargo & Company MN grew its position in CytomX Therapeutics by 83.2% during the fourth quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock worth $28,000 after buying an additional 3,000 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of CytomX Therapeutics in the 4th quarter worth approximately $35,000. Lido Advisors LLC purchased a new position in CytomX Therapeutics in the 1st quarter valued at approximately $49,000. May Hill Capital LLC purchased a new position in CytomX Therapeutics in the 4th quarter valued at approximately $46,000. Finally, GABELLI & Co INVESTMENT ADVISERS INC. acquired a new position in CytomX Therapeutics during the first quarter worth $52,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Price Performance

NASDAQ:CTMX opened at $3.25 on Tuesday. The firm has a market cap of $553.12 million, a PE ratio of -7.93 and a beta of 2.08. The firm has a 50 day simple moving average of $3.43 and a 200-day simple moving average of $4.34. CytomX Therapeutics, Inc. has a 1-year low of $1.72 and a 1-year high of $8.21.

CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.04. The firm had revenue of $10.26 million for the quarter, compared to analyst estimates of $4.68 million. CytomX Therapeutics had a negative net margin of 166.40% and a negative return on equity of 36.61%. As a group, sell-side analysts expect that CytomX Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on CTMX shares. HC Wainwright decreased their target price on CytomX Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Zacks Research raised CytomX Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 21st. Weiss Ratings reiterated a “sell (d)” rating on shares of CytomX Therapeutics in a research report on Tuesday, June 16th. Wolfe Research assumed coverage on shares of CytomX Therapeutics in a research report on Tuesday, May 19th. They issued an “outperform” rating and a $6.00 price objective on the stock. Finally, Wall Street Zen raised shares of CytomX Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $12.10.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.